Baselga J, Campone M, Piccart M et al.
Massachusetts General Hospital Cancer Center, Boston, MA, USA.
N Engl J Med 2012;366:520–9.
Lukas Schwentner’s review: In this study, the authors investigated the role of everolimus, a mammalian target of rapamycin (mTor) inhibitor, assigned in combination with exemestane for advanced hormone receptor-positive breast cancer. There is a lot of evidence that the mTor pathway is involved in endocrine resistance in breast cancer. The primary endpoint of this Phase III trial was progression-free survival (PFS) and the secondary endpoints were survival, safety, and toxicity.